In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals.
Become a patron of TWiV!
Links for this episode
- Risk associated with Omicron (medRxiv) 2:00
- Expansion of monoclonal EUA (FDA) 6:32
- Neutralization of Omicron by sera (medRxiv) 11:42
- Third dose sera neutralize Omicron (Pfizer) 15:13
- Monoclonals authorized for PreP (FDA) 18:30
- Patient outcomes after monoclonals (Open Forum Inf Dis) 22:33
- Subcutaneous or intramuscular monoclonals (medRxiv) 23:38
- WHO does not recommend convalescent serum (WHO) 25:42
- Immunomodulation and thromboembolic risk (J Clin Med) 28:21
- Long COVID after infection of vaccinated (medRxiv) 30:58
- Letters read on TWiV 840 36:38
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to email@example.com